Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19

Lovisa Bark(Uppsala University Hospital), Michael Hultström(Uppsala University), Ing‐Marie Larsson(Uppsala University), Miklós Lipcsey(Uppsala University), Elham Rostami(Uppsala University), Henrik Zetterberg(University of Wisconsin–Madison), Joel Simrén(University of Gothenburg), Robert Frithiof(Uppsala University), Ewa Wallin(Uppsala University Hospital)
Research Square
August 25, 2022
10.21203/rs.3.rs-1959033/v1
Cited by 0

Related Papers

Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021
|JAMA|2022|909
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
|Nature Medicine|2019|606
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
|Alzheimer s & Dementia|2022|589